Helix and Alnylam Forge Alliance to Accelerate Genetic Medicine

SAN MATEO, CA – March 05, 2026 – In a significant move to accelerate the development of precision medicines, enterprise genomics leader Helix today announced a multi-year agreement with Alnylam Pharmaceuticals, a pioneer in RNA interference (RNAi) therapeutics. The partnership grants Alnylam access to Helix's expansive GenoSphere™ database, a move designed to fuel the discovery of new drug targets by leveraging one of North America's largest integrated genomic and clinical datasets.

This collaboration sits at the nexus of two of biotechnology's most powerful trends: the industrial-scale application of human genetic data and the rise of programmable medicines like RNAi. For Alnylam, it represents a strategic doubling-down on its foundational philosophy of using human genetics to guide drug discovery. For Helix, it serves as a powerful validation of its enterprise platform model, cementing its role as a critical data engine for the pharmaceutical industry.

A Strategic Alliance to Accelerate Genetic Medicine

Alnylam has built its reputation on RNAi therapeutics, an innovative class of medicines that can effectively "silence" specific genes responsible for causing or contributing to disease. The company's core strategy hinges on identifying and validating drug targets with strong human genetic evidence, a method proven to dramatically increase the probability of a drug's success in clinical trials and subsequent approval.

The new agreement provides Alnylam with a vital resource to execute this strategy at an even greater scale. Access to the Helix platform is expected to significantly enhance the company's ability to discover novel targets for its growing pipeline, which spans rare genetic conditions, cardio-metabolic diseases, and central nervous system disorders.

"We believe that access to the Helix platform will bolster our efforts to identify new targets for RNAi therapeutics," said Paul Nioi, SVP of Research at Alnylam Pharmaceuticals, in the official announcement. "We use human genetics to guide our drug discovery efforts, and we look forward to accessing the Helix platform, which includes data from genetically diverse patients across North America."

This focus on genetic diversity is crucial. By analyzing data from a wide array of patient backgrounds, researchers can uncover genetic variants that protect against or predispose to disease, providing robust clues for new therapeutic interventions that could benefit broader populations.

The Power of Deeply Phenotyped Data

At the heart of the agreement is Helix's GenoSphere™, a continuously growing repository that goes far beyond raw genetic code. The platform's strength lies in its integration of multiple data streams to create a holistic, longitudinal view of a patient's health journey.

Key to this is Helix's proprietary Exome+® sequencing, which provides deep genetic information across thousands of genes. This genomic data is then linked to de-identified, rich clinical information sourced from electronic health records (EHR). With an average EHR history of 13 years per individual, the dataset includes diagnoses, lab results, and procedural history, offering a dynamic look at disease progression and health outcomes over time. The data is further enriched with medical and pharmacy claims, adding another layer of real-world context.

A critical differentiator for the Helix platform is that its entire research cohort is fully consented for re-contact. This unique feature allows partners like Alnylam to launch targeted follow-on studies with speed and precision, enabling them to validate initial findings and delve deeper into specific biological questions without the lengthy process of assembling a new cohort.

This combination of deep genomics, long-term clinical history, and the ability for agile follow-up creates a powerful discovery engine. It allows scientists to move from observing a statistical correlation in the data to investigating its biological underpinnings in a consented patient group, dramatically shortening a traditionally years-long research cycle.

Validating the Enterprise Genomics Model

The Alnylam partnership is a landmark achievement for Helix, providing strong market validation for its enterprise-level business model. Rather than acting as a simple data vendor, Helix has positioned itself as the architect of a comprehensive precision health ecosystem connecting health systems, life science companies, and patients.

"We are excited to establish this relationship with Alnylam," stated James Lu, M.D., Ph.D., CEO of Helix. "It further validates the unparalleled scale and depth of our platform and exemplifies Helix as a global catalyst in helping transform precision medicine development across major therapeutic areas to improve patient outcomes and lives."

This deal places Helix firmly among the top-tier data resources for pharmaceutical R&D, alongside established players like the UK Biobank and the Regeneron Genetics Center. While each has its strengths, Helix's focus on the North American population, its deep integration with longitudinal EHR data, and its consent model for follow-on studies provide a unique and compelling value proposition for drug developers.

Navigating a Competitive and Data-Driven Landscape

The Helix-Alnylam agreement does not exist in a vacuum. It is indicative of an industry-wide race among pharmaceutical giants to secure access to high-quality human genetic data. Alnylam itself has been particularly active, recently joining the Alliance for Genomic Discovery (AGD), a consortium of major pharma companies building a massive whole-genome database, and announcing a separate research collaboration with Tenaya Therapeutics focused on cardiovascular targets.

This flurry of activity underscores a fundamental shift in drug development. Companies are increasingly unwilling to risk billions of dollars on targets without strong human genetic validation. Access to large, diverse, and well-phenotyped datasets is no longer just a competitive advantage; it is becoming a prerequisite for successful and efficient R&D.

This data-driven approach promises to reshape the future of medicine by improving the efficiency of drug discovery and increasing the likelihood of success. By leveraging real-world data from hundreds of thousands of individuals, companies can identify the most promising therapeutic avenues with greater confidence. The collaboration between Helix and Alnylam represents a prime example of this new paradigm in action, uniting a leader in genetic medicine with a powerhouse in genomic data to accelerate the journey from scientific insight to life-changing therapy.